Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Tolerability of HyQvia in CIDP
2016-000374-37Phase 3Completed
- Sponsor
- Baxalta
- Start
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Baxalta. Primary endpoints: Long-term safety and tolerability and Immunogenicity to HyQvia components. Started Nov 2016; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2016-000374-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000374-37.